ROYAL BANK OF CANADA - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 91 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2018. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$236,000
+972.7%
116,174
+1089.7%
0.00%
Q2 2023$22,000
-92.1%
9,765
-89.4%
0.00%
Q1 2023$277,000
+27.1%
91,779
-2.2%
0.00%
Q4 2022$218,000
+23.2%
93,843
+1.4%
0.00%
Q3 2022$177,000
-47.0%
92,541
-24.7%
0.00%
Q2 2022$334,000
-13.9%
122,967
-5.5%
0.00%
Q1 2022$388,000
-32.6%
130,175
-12.1%
0.00%
Q4 2021$576,000
-7.1%
148,090
+2.5%
0.00%
Q3 2021$620,000
+246.4%
144,437
+145.2%
0.00%
Q2 2021$179,000
+8850.0%
58,895
+10089.4%
0.00%
Q1 2021$2,000
-96.4%
578
-96.2%
0.00%
Q4 2020$55,000
+27.9%
15,376
+10.8%
0.00%
Q3 2020$43,000
+186.7%
13,879
+67.8%
0.00%
Q2 2020$15,000
+400.0%
8,269
+242.7%
0.00%
Q1 2020$3,0000.0%2,413
+88.1%
0.00%
Q4 2019$3,000
-72.7%
1,283
-82.3%
0.00%
Q3 2019$11,000
-21.4%
7,252
+9.7%
0.00%
Q2 2019$14,000
-39.1%
6,610
+0.6%
0.00%
Q1 2019$23,000
-11.5%
6,571
-3.0%
0.00%
Q4 2018$26,000
-75.0%
6,773
-38.7%
0.00%
Q3 2018$104,000
+73.3%
11,056
+37.0%
0.00%
Q2 2018$60,000
-20.0%
8,073
-46.2%
0.00%
Q1 2018$75,000
+36.4%
14,999
+37.7%
0.00%
Q4 2017$55,000
-14.1%
10,895
+5.2%
0.00%
Q3 2017$64,000
+28.0%
10,355
-25.3%
0.00%
Q2 2017$50,000
+8.7%
13,855
-0.9%
0.00%
Q1 2017$46,000
-11.5%
13,980
-34.1%
0.00%
Q4 2016$52,000
+15.6%
21,230
+63.9%
0.00%
Q3 2016$45,000
-2.2%
12,950
-1.8%
0.00%
Q2 2016$46,000
-17.9%
13,190
-2.9%
0.00%
Q1 2016$56,000
-17.6%
13,590
-12.0%
0.00%
Q4 2015$68,000
-84.1%
15,450
-78.0%
0.00%
Q3 2015$428,00070,3000.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q3 2018
NameSharesValueWeighting ↓
Whitefort Capital Management, LP 11,895,477$24,147,81812.66%
Two Seas Capital LP 8,280,818$16,810,0613.38%
FourWorld Capital Management LLC 1,341,907$2,724,0710.51%
Tejara Capital Ltd 180,077$365,5560.21%
Woodline Partners LP 4,719,903$9,581,4030.11%
Hudson Bay Capital Management LP 8,299,808$16,848,6100.07%
Kepos Capital LP 155,691$3160.06%
Virtus ETF Advisers LLC 40,040$81,2810.05%
Centiva Capital, LP 1,071,705$2,175,5610.05%
Kades & Cheifetz LLC 20,000$40,6000.03%
View complete list of ARBUTUS BIOPHARMA CORP shareholders